The term “MET” most commonly refers to the proto-oncogene receptor tyrosine kinase MET (hepatocyte growth factor receptor). MET is a single-pass transmembrane receptor whose activation orchestrates key cellular processes including proliferation, motility, survival, morphogenesis, and wound-healing responses. In physiological contexts, MET signaling is tightly regulated by its ligand, hepatocyte growth factor (HGF). When HGF binds to MET, receptor dimerization and autophosphorylation occur on specific tyrosine residues within the intracellular domain. This phosphorylation creates docking sites for adaptor proteins and initiates multiple downstream pathways, most notably the RAS–RAF–MEK–ERK (MAPK) cascade, the PI3K–AKT–mTOR axis, and the JAK–STAT pathway. Through these effectors, MET signaling coordinates gene transcription programs and cytoskeletal remodeling that enable cell migration and survival.
At the molecular level, MET activation influences cell behavior through several mechanisms. First, MAPK signaling promotes cell cycle progression and proliferation by regulating transcription factors and kinase activity. Second, PI3K–AKT–mTOR signaling supports survival by inhibiting pro-apoptotic machinery, enhancing glucose metabolism, and promoting protein synthesis. Third, STAT signaling contributes to transcriptional responses that may increase growth factor production and immune-related signaling. Beyond canonical pathways, MET can also modulate epithelial–mesenchymal transition (EMT), a program in which epithelial cells acquire mesenchymal traits such as increased motility and invasiveness. EMT is clinically relevant because it underpins metastatic dissemination and resistance to some therapies.
Clinically, MET dysregulation is implicated in multiple human diseases, especially cancers. Tumor-associated mechanisms include gene amplification, activating mutations, aberrant splicing, and MET overexpression driven by altered upstream regulatory networks. In many malignancies, MET activation correlates with aggressive phenotypes, metastatic potential, and poor prognosis. For example, MET overactivity can sustain survival signaling even in the presence of therapeutic pressure, contributing to resistance to targeted therapies that inhibit parallel growth pathways.
In non-small cell lung cancer (NSCLC), MET alterations have been recognized as actionable targets in molecularly defined subsets. Similarly, MET is implicated in gastric and gastroesophageal cancers, renal cell carcinoma, and certain head and neck squamous cell cancers. In these settings, diagnostic workup often includes immunohistochemistry for protein overexpression, fluorescence in situ hybridization or sequencing for gene amplification/mutations, and in some contexts RNA-based assays to evaluate aberrant transcript variants. Because MET pathway activation can be heterogeneous, clinical practice emphasizes comprehensive molecular profiling rather than relying on a single marker.
Therapeutically, MET signaling is targeted using several classes of agents. Small-molecule MET tyrosine kinase inhibitors (TKIs) compete with ATP at the catalytic domain, reducing receptor phosphorylation and downstream pathway activation. Other approaches include monoclonal antibodies that block HGF–MET interaction or inhibit receptor function indirectly. Combination strategies are common in oncology because pathway redundancy can enable escape mechanisms. Resistance to MET inhibition may arise through secondary mutations that alter the drug-binding site, activation of bypass signaling networks, or phenotypic transitions that reduce dependency on MET. Therefore, longitudinal monitoring and adaptive treatment strategies are frequently considered.
Beyond cancer, MET signaling plays roles in developmental biology and tissue regeneration. Dysregulated MET/HGF signaling has been associated with organ fibrosis and inflammatory conditions, although the relationship is complex and context-dependent. In some fibrotic diseases, HGF/MET activity may contribute to remodeling by affecting fibroblast activation, epithelial injury responses, and extracellular matrix dynamics. Conversely, the same pathway can also support tissue repair depending on timing, intensity, and local microenvironmental cues. This duality reflects the broader principle that signaling networks often have both protective and pathogenic roles depending on disease stage.
From a diagnostic and translational standpoint, MET is typically discussed within a biomarker framework. Key clinical questions include whether the tumor exhibits MET dependence (“driver” biology) versus MET activation as a secondary adaptation, and whether the specific alteration predicts sensitivity to MET-directed therapy. Biomarker-driven selection aims to improve response rates and minimize ineffective treatment.
In summary, MET is a receptor tyrosine kinase central to HGF-dependent regulation of proliferation, survival, migration, and EMT-like transitions. Its activation proceeds through receptor phosphorylation and recruitment of signaling adaptors that trigger MAPK, PI3K/AKT/mTOR, and JAK/STAT pathways. MET dysregulation—through amplification, mutations, or overexpression—drives oncogenic behavior in diverse cancers and informs precision oncology strategies using MET TKIs and antibody-based therapies. Because resistance and pathway redundancy are common, molecular profiling and combination approaches are essential for durable clinical benefit. Source: RahmaSetia09 (Original post dated Jun 20, 2026).
rahma_wati09: Guys $MET is only 73 votes away from getting listed on Moonshot Don’t sleep on this and vote asap 👇. #breaking
— @RahmaSetia09 May 1, 2026
SHOP AMAZON BEST SELLERS, CLICK TO BUY FROM AMAZON.
SHOP AMAZON BEST SELLERS, CLICK TO BUY FROM AMAZON.
